European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Towards the use of IgY antibodies as alternative therapeutics

Descrizione del progetto

Una piattaforma innovativa semplifica il modo in cui le galline ci aiutano a combattere le malattie

Le immunoglobuline (o anticorpi) sono molecole prodotte dai nostri globuli bianchi; riconoscono gli «invasori» e contribuiscono alla loro distruzione. Negli esseri umani sono note cinque classi, una delle quali è simile in funzione all’IgY, un insolito anticorpo prodotto dai polli. L’IgY circolante si accumula nel tuorlo delle uova di gallina. Si tratta di una soluzione utile, perché gli scienziati possono immunizzare i polli contro una varietà di agenti patogeni, compresi quelli che infettano gli esseri umani, e poi purificare gli anticorpi IgY dal tuorlo d’uovo, senza dover affrontare la complessa produzione di anticorpi monoclonali di derivazione umana. Il progetto PureIgY, finanziato dall’UE, sta sviluppando un metodo più semplice e meno costoso per isolare l’IgY che migliorerà anche la resa in modo significativo. Il team intende utilizzare questa piattaforma innovativa per sviluppare rapidamente terapie per gli agenti patogeni resistenti agli antimicrobici.

Obiettivo

The increased occurrence of antibiotic-resistant pathogens is a critical concern corresponding to economic and societal challenges of high priority. Antimicrobial resistance (AMR) is responsible for 33,000 deaths per year, while bringing €1.5 billion per year in healthcare costs and productivity losses to the EU. Current solutions (biopharmaceuticals) are highly expensive and very few tackle the AMR scenario. Therefore, new approaches to tackling AMR focusing on low cost and relatively low time-to-market therapeutics must be pursued. Immunoglobulin Y (IgY) present in hen’s egg yolk is a potential alternative to the previously described biotherapeutics, and can be obtained in higher amounts from a renewable and non-invasive matrix. However, given the complex nature of egg yolk, the current purification technologies are multi-step and mainly based on chromatography, being highly expensive and leading to low yields. In the ERC Starting Grant (IgYPurTech) I proposed the use of aqueous biphasic systems (ABS) as IgY separation/purification platforms (from commercial and non-hyperimmune eggs since no therapeutic action was defined in the proposal). Although promising results have been obtained with ABS, during the IgYPurTech framework an additional and more cost-effective process to purify IgY was developed. It is not based on the selective extraction of antibodies for one of the phases in ABS, but on two steps of induced precipitation with appropriate salts and biopolymers. This innovative purification platform enables to produce high-quality IgY in higher amounts and at a significantly lower cost than other currently commercialized biotherapeutics. In this PoC Action – PureIgY – it is aimed to scale-up the developed purification technology, to address the biological features of specific IgY to tackle the AMR critical scenario, to work on the business plan development and business development, and to create an early-stage drug development start-up.

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Istituzione ospitante

UNIVERSIDADE DE AVEIRO
Contribution nette de l'UE
€ 150 000,00
Indirizzo
CAMPUS UNIVERSITÁRIO DE SANTIAGO
3810-193 Aveiro
Portogallo

Mostra sulla mappa

Regione
Continente Centro (PT) Região de Aveiro
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)